家庭可穿戴连续心电监测贴片对未诊断房颤检测的影响:mSToPS随机临床试验
该研究纳入2659名高房颤风险个体,随机分为立即或延迟4个月的家庭可穿戴心电贴片监测,另匹配3476名对照。立即监测组4个月新发房颤诊断率3.9% vs 延迟组0.9%(绝对差3.0%)。1年时监测组房颤诊断率、抗凝药启动及医疗资源使用均高于对照。
要点
- 家庭可穿戴心电贴片监测可提高高房颤风险人群的房颤检出率。
- 监测组4个月新发房颤诊断绝对差为3.0%(95%CI 1.8%-4.1%)。
- 监测组1年抗凝药启动及门诊就诊增加,但房颤相关急诊/住院无差异。
核心结论
- 在高房颤风险个体中,立即家庭可穿戴心电监测相比延迟监测4个月时房颤诊断率更高。
- 监测个体1年房颤诊断率、抗凝药启动及医疗资源使用均高于未监测对照。
研究设计与样本
- 直接面向参与者的随机临床试验与前瞻性匹配观察性队列研究。
- 随机试验纳入2659人(平均年龄72.4岁,38.6%女性),随机分立即监测(n=1364)或延迟4个月监测(n=1291)。
- 观察性研究纳入5214人(平均年龄73.7岁,40.5%女性,中位CHA2DS2-VASc评分3.0),含1738名主动监测者与3476名匹配对照。
主要发现
- 4个月时立即组新发房颤3.9%(53/1366) vs 延迟组0.9%(12/1293),绝对差3.0%(95%CI 1.8%-4.1%)。
- 1年时监测组房颤新诊断109例(6.7/100人年) vs 未监测组81例(2.6/100人年),差异4.1(95%CI 3.9-4.2)。
- 监测组抗凝药启动(5.7 vs 3.7/100人年,差2.0[95%CI 1.9-2.2])、心脏科门诊(33.5 vs 26.0/100人年,差7.5[95%CI 7.2-7.9])及初级保健就诊(83.5 vs 82.6/100人年,差0.9[95%CI 0.4-1.5])均增加。
- 房颤相关急诊就诊及住院无差异(1.3 vs 1.4/100人年,差0.1[95%CI -0.1至0])。
临床怎么用
- 对高房颤风险人群可考虑使用家庭可穿戴心电贴片进行机会性筛查以提高检出。
- 筛查阳性后需启动抗凝等适当治疗,并预期门诊就诊等医疗资源使用增加。
局限性
- 随机组中仅65.4%(1738/2659)完成主动监测。
- 观察性部分为非随机匹配对照,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Opportunistic screening for atrial fibrillation (AF) is recommended, and improved methods of early identification could allow for the initiation of appropriate therapies to prevent the adverse health outcomes associated with AF. OBJECTIVE: To determine the effect of a self-applied wearable electrocardiogram (ECG) patch in detecting AF and the clinical consequences associated with such a detection strategy. DESIGN, SETTING, AND PARTICIPANTS: A direct-to-participant randomized clinical trial and prospective matched observational cohort study were conducted among members of a large national health plan. Recruitment began November 17, 2015, and was completed on October 4, 2016, and 1-year claims-based follow-up concluded in January 2018. For the clinical trial, 2659 individuals were randomized to active home-based monitoring to start immediately or delayed by 4 months. For the observational study, 2 deidentified age-, sex- and CHA2DS2-VASc-matched controls were selected for each actively monitored individual. INTERVENTIONS: The actively monitored cohort wore a self-applied continuous ECG monitoring patch at home during routine activities for up to 4 weeks, initiated either immediately after enrolling (n = 1364) or delayed for 4 months after enrollment (n = 1291). MAIN OUTCOMES AND MEASURES: The primary end point was the incidence of a new diagnosis of AF at 4 months among those randomized to immediate monitoring vs delayed monitoring. A secondary end point was new AF diagnosis at 1 year in the combined actively monitored groups vs matched observational controls. Other outcomes included new prescriptions for anticoagulants and health care utilization (outpatient cardiology visits, primary care visits, or AF-related emergency department visits and hospitalizations) at 1 year. RESULTS: The randomized groups included 2659 participants (mean [SD] age, 72.4 [7.3] years; 38.6% women), of whom 1738 (65.4%) completed active monitoring. The observational study comprised 5214 (mean [SD] age, 73.7 [7.0] years; 40.5% women; median CHA2DS2-VASc score, 3.0), including 1738 actively monitored individuals from the randomized trial and 3476 matched controls. In the randomized study, new AF was identified by 4 months in 3.9% (53/1366) of the immediate group vs 0.9% (12/1293) in the delayed group (absolute difference, 3.0% [95% CI, 1.8%-4.1%]). At 1 year, AF was newly diagnosed in 109 monitored (6.7 per 100 person-years) and 81 unmonitored (2.6 per 100 person-years; difference, 4.1 [95% CI, 3.9-4.2]) individuals. Active monitoring was associated with increased initiation of anticoagulants (5.7 vs 3.7 per 100 person-years; difference, 2.0 [95% CI, 1.9-2.2]), outpatient cardiology visits (33.5 vs 26.0 per 100 person-years; difference, 7.5 [95% CI, 7.2-7.9), and primary care visits (83.5 vs 82.6 per 100 person-years; difference, 0.9 [95% CI, 0.4-1.5]). There was no difference in AF-related emergency department visits and hospitalizations (1.3 vs 1.4 per 100 person-years; difference, 0.1 [95% CI, -0.1 to 0]). CONCLUSIONS AND RELEVANCE: Among individuals at high risk for AF, immediate monitoring with a home-based wearable ECG sensor patch, compared with delayed monitoring, resulted in a higher rate of AF diagnosis after 4 months. Monitored individuals, compared with nonmonitored controls, had higher rates of AF diagnosis, greater initiation of anticoagulants, but also increased health care resource utilization at 1 year. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02506244.
引用
- Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. JAMA. 2018. PMID: 29998336. doi:10.1001/jama.2018.8102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。